



Year: 2021

Anticoagulant Selection in Relation to SAME-TT₂R₂ Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry

Ntaios, George ; Huisman, Menno V ; Diener, Hans-Christoph ; Halperin, Jonathan L ; Teutsch, Christine ; Marler, Sabrina ; Gurusamy, Venkatesh K ; Thompson, Milla ; Lip, Gregory Y H ; Olshansky, Brian

Abstract: Aim The SAME-TT₂R₂ score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA), and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAME-TT₂R₂ scores >2 than to patients with lower scores. Methods and results We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and 1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of VKA prescription among anticoagulated patients with baseline SAME-TT₂R₂ score >2 and 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) were prescribed VKA and 12,637 (72.4%) a NOAC: 11,884 (68.0%) patients had SAME-TT₂R₂ scores 0-2 and 5,581 (32.0%) had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAME-TT₂R₂ scores >2 and 27.5% in those with scores 2. Conclusions The lack of clear association between the SAME-TT₂R₂ score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs, as well as to the absence of trial evidence that a SAME-TT₂R₂-guided strategy for the selection of the type of anticoagulation in NVAf patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial.

DOI: <https://doi.org/10.1016/j.hjc.2020.11.009>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-196439>

Journal Article

Accepted Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

Originally published at:

Ntaios, George; Huisman, Menno V; Diener, Hans-Christoph; Halperin, Jonathan L; Teutsch, Christine; Marler, Sabrina; Gurusamy, Venkatesh K; Thompson, Milla; Lip, Gregory Y H; Olshansky, Brian (2021).

Anticoagulant Selection in Relation to SAMe-TT₂R₂ Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry. Hellenic Journal of Cardiology, 62(2):152-157.
DOI: <https://doi.org/10.1016/j.hjc.2020.11.009>

Anticoagulant Selection in Relation to SAME-TT₂R₂ Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry

George Ntaios, MD, MSc, PhD, Menno V. Huisman, MD, PhD, FESC, Hans-Christoph Diener, MD, PhD, Jonathan L. Halperin, MD, Christine Teutsch, MD, Sabrina Marler, MS, Venkatesh K. Gurusamy, MS, Milla Thompson, MSc, Gregory Y.H. Lip, MD, Brian Olshansky, MD, on behalf of the GLORIA-AF Investigators

PII: S1109-9666(20)30281-5

DOI: <https://doi.org/10.1016/j.hjc.2020.11.009>

Reference: HJC 582

To appear in: *Hellenic Journal of Cardiology*

Received Date: 18 September 2020

Revised Date: 4 November 2020

Accepted Date: 19 November 2020

Please cite this article as: Ntaios G, Huisman MV, Diener HC, Halperin JL, Teutsch C, Marler S, Gurusamy VK, Thompson M, Lip GYH, Olshansky B, on behalf of the GLORIA-AF Investigators, Anticoagulant Selection in Relation to SAME-TT₂R₂ Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry, *Hellenic Journal of Cardiology*, <https://doi.org/10.1016/j.hjc.2020.11.009>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. All rights reserved.



Anticoagulant Selection in Relation to SAME-TT₂R₂ Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry

George Ntaios, MD, MSc, PhD¹; Menno V. Huisman*, MD, PhD, FESC²; Hans-Christoph Diener, MD, PhD³; Jonathan L. Halperin, MD⁴; Christine Teutsch, MD⁵; Sabrina Marler MS⁶; Venkatesh K. Gurusamy, MS⁵; Milla Thompson, MSc⁷; Gregory Y. H. Lip*, MD⁸; Brian Olshansky*, MD⁹ on behalf of the GLORIA-AF Investigators**

¹Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece; ²Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands; ³Department of Neurology, University of Duisburg-Essen, Essen, Germany; ⁴Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁵Boehringer Ingelheim International GmbH, Ingelheim, Germany; ⁶Boehringer Ingelheim Inc., Ridgefield, CT, USA; ⁷Boehringer Ingelheim Finland Ky, Helsinki, Finland; ⁸Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK; ⁹University of Iowa, Mercy Hospital, Mason City, Iowa and Covenant Hospital, Waterloo, IA, USA

*Drs Huisman and Lip are Chairs of the GLORIA-AF Registry, and joint senior authors with Dr Olshansky

**For the list of GLORIA-AF investigators please see the Appendix


Abstract/manuscript word count: 273/1845

Figures/tables: 2/1

Corresponding author:

George Ntaios MD, MSc (Stroke Medicine), PhD

Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. T: +30 241 3502888, F: +30 241 3501557, E-mail: gntaios@med.uth.gr



Anticoagulant Selection in Relation to SAME-TT₂R₂ Score in Patients with Atrial**Fibrillation: The GLORIA-AF Registry**

George Ntaios, MD, MSc, PhD¹; Menno V. Huisman*, MD, PhD, FESC²; Hans-Christoph Diener, MD, PhD³; Jonathan L. Halperin, MD⁴; Christine Teutsch, MD⁵; Sabrina Marler MS⁶; Venkatesh K. Gurusamy, MS⁵; Milla Thompson, MSc⁷; Gregory Y. H. Lip*, MD⁸; Brian Olshansky*, MD⁹ on behalf of the GLORIA-AF Investigators**

¹Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece; ²Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands; ³Department of Neurology, University of Duisburg-Essen, Essen, Germany; ⁴Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁵Boehringer Ingelheim International GmbH, Ingelheim, Germany; ⁶Boehringer Ingelheim Inc., Ridgefield, CT, USA; ⁷Boehringer Ingelheim Finland Ky, Helsinki, Finland; ⁸Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK; ⁹University of Iowa, Mercy Hospital, Mason City, Iowa and Covenant Hospital, Waterloo, IA, USA

*Drs Huisman and Lip are Chairs of the GLORIA-AF Registry, and joint senior authors with Dr Olshansky

**For the list of GLORIA-AF investigators please see the Appendix

Abstract/manuscript word count: 273/1845

Figures/tables: 2/1

Corresponding author:

George Ntaios MD, MSc (Stroke Medicine), PhD

Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. T: +30 241 3502888, F: +30 241 3501557, E-mail: gntaios@med.uth.gr

Abstract

Aim: The SAME-TT₂R₂ score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA), and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAME-TT₂R₂ scores >2 than to patients with lower scores.

Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of VKA prescription among anticoagulated patients with baseline SAME-TT₂R₂ score >2 and ≤2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) were prescribed VKA and 12,637 (72.4%) a NOAC: 11,884 (68.0%) patients had SAME-TT₂R₂ scores 0-2 and 5,581 (32.0%) had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAME-TT₂R₂ scores >2 and 27.5% in those with scores ≤2. The adjusted probability for VKA prescription in patients with scores >2 vs. score ≤2 was 0.907 (95%CI: 0.856-0.961).

Conclusions: The lack of clear association between the SAME-TT₂R₂ score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs, as well as to the absence of trial evidence that a SAME-TT₂R₂-guided strategy for the selection of the type of anticoagulation in NVAf patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial.

Clinical trial registration: URL: <https://www.clinicaltrials.gov> / Unique identifier: NCT01937377, NCT01468701 and NCT01671007

Keywords: SAME-TT₂R₂; atrial fibrillation; non-vitamin-K antagonist oral anticoagulants; vitamin-K-antagonist oral anticoagulants

Author contributions

George Ntaios: study concept; data collection, analysis and interpretation; drafting of the manuscript

Menno V. Huisman: study concept; data collection, analysis and interpretation; drafting of the manuscript

Hans-Christoph Diener: study concept; data collection, analysis and interpretation; drafting of the manuscript

Jonathan L. Halperin: study concept; data collection, analysis and interpretation; drafting of the manuscript

Christine Teutsch: study concept; data collection, analysis and interpretation; drafting of the manuscript

Sabrina Marler: study concept; data collection, analysis and interpretation; drafting of the manuscript

Venkatesh K. Gurusamy: study concept; data collection, analysis and interpretation; drafting of the manuscript

Milla Thompson: study concept; data collection, analysis and interpretation; drafting of the manuscript

Gregory Y. H. Lip: study concept; data collection, analysis and interpretation; drafting of the manuscript

Brian Olshansky: study concept; data collection, analysis and interpretation; drafting of the manuscript

Funding source

This study was funded by Boehringer Ingelheim.

Disclosures

George Ntaios: Speaker fees/Advisory Boards/Research support from Amgen; Bayer; BMS/Pfizer; Boehringer-Ingelheim; Elpen; Galenica; Sanofi; Winmedica. No fees directly received personally.

Menno V. Huisman: Grants from ZonMW Dutch Healthcare Fund; grants and personal fees from Boehringer-Ingelheim, Pfizer-BMS, Bayer Health Care, Aspen, Daiichi-Sankyo, outside the submitted work.

Hans-Christoph Diener: Received honoraria for participation in clinical trials; contribution to advisory boards or oral presentations from: Abbott, Bayer Vital, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Medtronic, Pfizer, Portola, Sanofi-Aventis and WebMD Global. Financial support for research projects was provided by Boehringer Ingelheim. Chairs the Treatment Guidelines Committee of the German Society of Neurology and contributed to the EHRA and ESC guidelines for the treatment of AF.

Jonathan L. Halperin: Consulting activities with Boehringer Ingelheim, for advisory activities involving anticoagulants, and he is a member of the Executive Steering Committee of the GLORIA-AF Registry.

Christine Teutsch; Sabrina Marler; Venkatesh K. Gurusamy; Milla Thompson: are employees of Boehringer Ingelheim.

Gregory Y. H. Lip: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi-Sankyo. He has been a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees directly received personally.

Brian Olshansky: Consulting fees from Boehringer Ingelheim and Lundbeck; and has served as DSMB Chair for Amarin (REDUCE IT Trial).

Introduction

For many decades, vitamin-K antagonists (VKA) were the only anticoagulant choice for patients with non-valvular atrial fibrillation (NVAF). The achievement and maintenance of a therapeutic international normalized ratio (INR) in VKA-treated patients can be challenging due to numerous VKA-related limitations such as narrow therapeutic window, need for frequent INR measurements with consequent dose adjustments, and food-drug and drug-drug interactions.

Common clinical factors determine if a patient can achieve effective and safe anticoagulation control on VKAs. The SAME-TT₂R₂ score was developed to help identify those at high-risk for poor anticoagulation control and thus higher risk of stroke or peripheral embolism as estimated by the time in therapeutic INR range (TTR). The SAME-TT₂R₂ score consists of the following: Sex (female), Age (<60 years); Medical history (≥2 of the following: hypertension, diabetes, coronary artery disease/myocardial infarction, peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, hepatic or renal disease); Treatment (interacting drugs, like amiodarone for rhythm control) [all 1 point]; current Tobacco use (2 points) and Race (2 points for non-Caucasian)¹. Patients with a SAME-TT₂R₂ score >2 could best avoid a “trial of VKA” and start directly with a non-vitamin-K-antagonist oral anticoagulant (NOAC).

The recent 2018 CHEST Guideline and Expert Panel Report on antithrombotic therapy in patients with atrial fibrillation suggest that the SAME-TT₂R₂ score could be used to aid decision-making: patients with a score of >2 points are prone to low TTR while on VKA and can be monitored more closely with more frequent INR measurements or can be supported with more intensive education or counselling to improve TTR. Alternatively, if there are concerns, they may skip a “trial of VKA” and start directly with a non-vitamin-K antagonist oral anticoagulant (NOAC)².

In this context, we hypothesized that VKAs may be less frequently prescribed in patients with non-valvular atrial fibrillation (NVAF) and a SAME-TT₂R₂ score of >2 compared to patients with a score of 0-2.

We tested this hypothesis in a large, contemporary, prospective, global registry of newly diagnosed NVAf patients with ≥ 1 stroke risk factors.

Methods

The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) was designed to generate evidence on patients with recently diagnosed NVAF treated in routine clinical practice. The aim of this multinational, multicenter, prospective, non-interventional registry is to provide long-term effectiveness and safety data on NOAC and VKA for stroke prevention in patients with NVAF in nearly 50 countries³.

The design of GLORIA-AF, a global, non-interventional registry program with 3 phases, has been described in detail previously³. Phase III consists of a cross-sectional and comparative analyses part involving a 3-year follow-up of all patients independent of antithrombotic therapy. Ethical approvals were obtained from the Institutional Review Boards as required at participating sites. The GLORIA-AF study is listed at Clinicaltrials.gov (NCT01937377, NCT01468701 and NCT01671007).

The phase III of GLORIA-AF enrolled adult patients with newly diagnosed NVAF (i.e. NVAF diagnosed within 3 months of the baseline visit; Latin America < 4.5 months) and a CHA₂DS₂-VASc score of ≥ 1 between 2014 and 2016. Patients with mechanical heart valves, prior VKA therapy for >60 days, life-expectancy ≤ 1 year at recruitment, a comorbidity other than NVAF for which chronic use of VKAs is indicated and NVAF due to a generally reversible cause were excluded. The CHADS₂ and CHA₂DS₂-VASc scores were used to assess the thromboembolic risk of the patients. The HAS-BLED bleeding score was used to assess bleeding risk⁴. Patients were recruited from outpatient settings from university hospitals, community hospitals, specialist offices and general practice offices. Sites were chosen to reflect physicians who typically identify and manage patients with newly diagnosed NVAF cases in each participating country.

Data collection and quality control

All clinical data were collected and processed using a web-based external vendor managed Infosario Outcome EDC[®] system to ensure that data was complete, accurate, internally consistent, logical and in compliance with the requirements of the protocol. Study data were entered into the EDC system by the study staff using a secured network and the study physician electronically signed the case report forms to confirm accuracy and completeness of the entered information. Extensive data quality standards were in place to address any systematic data issues identified.

Statistical Analysis

Baseline data were summarized descriptively. Continuous variables were reported as mean and standard deviation. Categorical variables were reported as absolute frequencies and percentages. SAME-TT₂R₂ scores were derived from the patient characteristics at baseline. Baseline characteristics for patients treated with oral anticoagulants were described based on SAME-TT₂R₂ score (>2 versus ≤2). To compare these groups, standardized differences were used. The focus will be on the variables with highest standardized differences, while differences ≤10% in absolute value will be considered as balanced between the groups⁵.

We performed a log-binomial regression analysis to estimate risk ratios in the cohort of patients who were anticoagulated to identify the association between SAME-TT₂R₂ score and prescription of VKA. We use the term “probability ratio” rather than “risk ratio” as our measure describes drug use rather than adverse outcomes. Both univariate and multivariate log-binomial regression analyses were performed to evaluate the crude as well as the adjusted probability ratios together with 95% confidence intervals (CIs). The variables included in this analysis were the SAME-TT₂R₂ score and other covariates which are not SAME-TT₂R₂ components, as follows: the type of atrial fibrillation (paroxysmal vs. persistent vs. permanent), body mass index class, reimbursement status, geographical region (Asia, Europe, North America, Latin America), other comorbidities [prior bleeding and cancer] and alcohol abuse. Statistical analyses were performed with the SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).

Journal Pre-proof

Results

The baseline characteristics and their standardized differences by baseline SAME-TT₂R₂ score are summarized in table 1. Among 21,597 patients who were enrolled in 38 countries, there were 21,248 who were eligible for the analysis. Of these, 17,465 (82.2%) were treated with oral anticoagulation (45.0% women) and were included in the analysis. Among OAC treated patients, 4,828 (27.6%) received VKA and 12,637 (72.4%) received NOAC. Out of 17,465 OAC treated patients, 11,884 (68.0%) patients had SAME-TT₂R₂ score of ≤ 2 and 5,581 (32.0%) with a score of >2 .

Patients with a SAME-TT₂R₂ score of ≤ 2 were older (mean age (\pm SD) 72.4 \pm 9.4 vs 68.3 \pm 11.4) and were more often men (58.5% vs 47.8%) as compared to those with SAME-TT₂R₂ score >2 . The mean CHADS₂ score was 1.9 \pm 1.1 and the mean CHA₂DS₂-VASc was 3.2 \pm 1.5 in both SAME-TT₂R₂ groups. The mean HAS-BLED was 1.3 \pm 0.8 in patients with SAME-TT₂R₂ score of ≤ 2 and 1.2 \pm 0.9 for patients with SAME-TT₂R₂ score of >2 .

Clinical risk profile and SAME-TT₂R₂ score

Patients from Europe accounted for 60.8% of those with a SAME-TT₂R₂ score of ≤ 2 ; 38.9% and 35.0% of patients with a SAME-TT₂R₂ score >2 were from Asia and Europe, respectively. Fewer patients in the SAME-TT₂R₂ score of ≤ 2 underwent NVAf ablation (0.9% vs 4.2%) and there was a higher prevalence of hyperlipidemia (42.7% vs 36.6%) and cancer (11.7% vs 7.2%) compared to those with score of >2 . There was high prevalence of congestive heart failure (25.7% vs 20.4%), diabetes mellitus (28.4% vs 21.7%), hepatic disease (2.5% vs 0.8%) and chronic kidney disease (27.1% vs 22.0%) in SAME-TT₂R₂ score >2 versus those with a SAME-TT₂R₂ score ≤ 2 .

SAME-TT₂R₂ score and VKA use: Regional differences

The proportion of patients treated with VKAs was 28.0% with a SAME-TT₂R₂ score of >2 and 27.5% with a score of ≤2. Patients from Europe and Latin America who had a SAME-TT₂R₂ score >2 were less often prescribed VKA compared with a SAME-TT₂R₂ score ≤2 (21.0% vs. 28.2%, for Europe, standardized difference: -0.169; 27.8% vs. 41.1%, for Latin America, standardized difference: -0.283). Patients from North America with a SAME-TT₂R₂ score >2 were more often prescribed VKA compared with those with a SAME-TT₂R₂ score ≤2 (14.3% vs. 9.6%, respectively, standardized difference: -0.147) (figure 1).

SAME-TT₂R₂ score and VKA use: Enrolment year

There were no important differences in the prescription rate of VKAs between patients with a SAME-TT₂R₂ score >2 versus those with a score of ≤2 with regard to the enrollment year (26.4% vs. 23.5%, for 2014, standardized difference: 0.067; 23.0% vs. 26.4%, for 2015, standardized difference: -0.079; 22.3% vs. 19.1%, for 2016, standardized difference: 0.079) (figure 2).

Multivariable analysis

In the multivariable analysis, patients with a SAME-TT₂R₂ score >2 were less frequently prescribed VKA compared with patients with a score ≤2 (adjusted probability ratio 0.907; 95%CI: (0.856 , 0.961). Factors associated with increased prescription of VKA use were geographical region and type of NVAf (table 2).

Discussion

This is the first global study to assess the association between the SAME-TT₂R₂ score and the type of oral anticoagulant use in a large, prospective, multinational cohort of non-valvular AF patients anticoagulated in routine clinical practice. We found no clear association between the SAME-TT₂R₂ score and anticoagulant selection.

The lack of clear association between the SAME-TT₂R₂ score and anticoagulant selection may indicate that other factors, not captured entirely by the SAME-TT₂R₂ likely have more influence on prescriptive choices in clinical practice. Such a factor may be the safety and efficacy profile of VKAs and NOACs. There is solid evidence from randomized controlled trials, as well as from real-world studies, showing that NOACs are safer and at least as effective as VKAs⁶⁻⁸. Accordingly, current clinical practice guidelines recommend NOACs in preference to VKA^{2, 9, 10}. Due to overwhelming evidence favoring NOACs over VKAs, treating physicians may have largely adopted the related recommendations and prefer to start directly with a NOAC amongst NOAC-eligible NVAf patients, even in patients with a favorable SAME-TT₂R₂ score who would be expected to maintain a good level of anticoagulation control on VKA. This is in line with recent reports of sharply increasing trends of NOAC prescription over VKA worldwide¹¹⁻¹⁴.

Another potential explanation for the results of our analysis is that although several validation studies in different populations suggest that the SAME-TT₂R₂ score can predict the quality of anticoagulation in NVAf patients, there is still no trial evidence that a SAME-TT₂R₂-guided strategy for the selection of the type of anticoagulation in NVAf patients has an impact on clinical outcomes of efficacy and safety. In this context, a large randomized trial that assesses a SAME-TT₂R₂-guided strategy on quality of anticoagulation and on clinical outcomes (e.g., thromboembolism and bleeding) would determine its utility in routine clinical practice. Such an ongoing trial, the TREATS-AF trial, is being conducted in Thailand¹⁵.

Limitations

While we did not perform region-specific analyses, the large sample size of prospectively recruited patients from nearly 50 countries with extensive data quality review and broad physician and site selection worldwide enhanced the value of this study.

Conclusion

In this large, prospective, multinational cohort of non-valvular AF patients anticoagulated in routine clinical practice, we found no clear association between the SAME-TT₂R₂ score and anticoagulant selection. The lack of clear association between the SAME-TT₂R₂ score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs, as well as to the absence of trial evidence that a SAME-TT₂R₂-guided strategy for selection of the type of anticoagulation in NVAf patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized, controlled trial.

References

1. Apostolakis S, Lane DA, Buller H, Lip GY. Comparison of the CHADS₂, CHA₂DS₂-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. *Thromb Haemost* 2013;**110**(5):1074-9.
2. Lip GYH, Banerjee A, Boriani G, Chiang Ce, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. *CHEST* 2018;**154**(5):1121-1201.
3. Huisman MV, Lip GY, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Teutsch C, Zint K, Ackermann D, Clemens A, Bartels DB. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. *Am Heart J* 2014;**167**(3):329-34.
4. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010;**138**(5):1093-100.
5. Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. *Communications in Statistics - Simulation and Computation* 2009;**38**(6):1228-1234.
6. Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. *Stroke* 2017;**48**(9):2494-2503.
7. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. *Int J Stroke* 2017;**12**(6):589-596.
8. Diener HC, Ntaios G, O'Donnell M, Easton JD. Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke. *Expert Opin Pharmacother* 2018;**19**(14):1597-1602.
9. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Devereux S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwaliski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016;**37**(38):2893-2962.
10. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. *Circulation*;0(0):CIR.0000000000000665.
11. McIntyre WF, Conen D, Olshansky B, Halperin JL, Hayek E, Huisman MV, Lip GYH, Lu S, Healey JS. Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program. *Clin Cardiol* 2018;**41**(6):744-751.
12. Lim GB. Registries reveal real-world use of anticoagulant drugs in AF. *Nature Reviews Cardiology* 2017;**14**:189.
13. Loo SY, Dell'Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. *British journal of clinical pharmacology* 2017;**83**(9):2096-2106.
14. van den Heuvel JM, Hövels AM, Büller HR, Mantel-Teeuwisse AK, de Boer A, Maitland-van der Zee AH. NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands. *Thrombosis journal* 2018;**16**:7-7.
15. <https://gtr.ukri.org/projects?ref=MR%2FR020892%2F1>, accessed on 30/05/2019.

Table 1: Baseline characteristics and their standardized differences by baseline SAmE-TT₂R₂ score for eligible anticoagulated patients in Phase III.

	SAmE-TT ₂ R ₂ ≤2 n=11,884	SAmE-TT ₂ R ₂ >2 n=5,581	Standardized difference
Demographics			
Age, mean±SD, years	72.4±9.4	68.3±11.4	-0.3920
Female gender	4,936 (41.5%)	2,915 (52.2%)	0.2156
Race			
White	11,351 (95.5%)	1,546 (27.7%)	-1.9450
Asian	330 (2.8%)	2,181 (39.1%)	0.9972
Black/African American	20 (0.2%)	300 (5.4%)	0.3213
Insurance status			
Private	1,717 (14.4%)	835 (15.0%)	0.0145
Statutory / federal insurance	8,871 (74.6%)	4,002 (71.7%)	-0.0664
Self-pay / no coverage	429 (3.6%)	416 (7.5%)	0.1687
Comorbidities			
Body mass index (kg/m ²), mean±SD	29.39±6.41	27.76±6.40	-0.2553
Dyslipidemia	5,077 (42.7%)	2,040 (36.6%)	-0.1264
Hepatic disease	91 (0.8%)	142 (2.5%)	0.1398
Congestive heart failure	2,424 (20.4%)	1,437 (25.7%)	0.1273
NYHA I	203 (8.4%)	138 (9.6%)	0.0430
NYHA II	1,325 (54.7%)	759 (52.8%)	-0.0370
NYHA III	520 (21.5%)	316 (22.0%)	0.0131
NYHA IV	45 (1.9%)	60 (4.2%)	0.1359
Ejection fraction ≤40%	973 (40.1%)	596 (41.5%)	0.0272
Diabetes mellitus	2,574 (21.7%)	1586 (28.4%)	0.1565
Arterial hypertension	8,950 (75.3%)	4,331 (77.6%)	0.0540
Abnormal kidney function	181 (1.5%)	97 (1.7%)	0.0170
Previous stroke	1,135 (9.6%)	656 (11.8%)	0.0715
Transient ischemic attack	651 (5.5%)	185 (3.3%)	-0.1057
Pulmonary embolism	70 (0.6%)	39 (0.7%)	0.0137
Deep venous thrombosis	168 (1.4%)	53 (0.9%)	-0.0430
Non-CNS arterial embolism	49 (0.4%)	20 (0.4%)	-0.0087
Smoking			
Non smoker	6,821 (57.4%)	3,078 (55.2%)	-0.0453
Current smoker	180 (1.5%)	1,369 (24.5%)	0.7277
Past smoker	4,482 (37.7%)	985 (17.6%)	-0.4602
Alcohol abuse (≥8 Units/week)	883 (7.4%)	357 (6.4%)	-0.0407
Coronary artery disease	2,052 (17.3%)	998 (17.9%)	0.0162
Myocardial infarction	1,127 (9.5%)	476 (8.5%)	-0.0333
Periphery arterial disease	348 (2.9%)	165 (3.0%)	0.0017
Prior bleeding	610 (5.1%)	252 (4.5%)	-0.0288
Cancer	1392 (11.7%)	404 (7.2%)	-0.1532
Creatinine clearance (ml/min), mean±SD	86.0±200.5	80.3±39.9	-0.0394
Creatinine clearance <15ml/min	70 (0.6%)	42 (0.8%)	0.0200
Creatinine clearance 15 to <30ml/min	188 (1.6%)	122 (2.2%)	0.0444
Creatinine clearance 30 to <50ml/min	1,235 (10.4%)	722 (12.9%)	0.0793
Creatinine clearance 50 to <80ml/min	3,854 (32.4%)	1,723 (30.9%)	-0.0335
Creatinine clearance ≥80ml/min	4,215 (35.5%)	1,893 (33.9%)	-0.0326
Type of NVAf			
Paroxysmal	6,204 (52.2%)	3,115 (55.8%)	0.0725
Persistent	4,354 (36.6%)	1,947 (34.9%)	-0.0365
Permanent	1,326 (11.2%)	519 (9.3%)	-0.0614
Categorization of NVAf			
Symptomatic	3,475 (29.2%)	1,930 (34.6%)	0.1148
Minimally symptomatic	3,930 (33.1%)	1,893 (33.9%)	0.0180
Asymptomatic	4,479 (37.7%)	1,758 (31.5%)	-0.1304
Type of site			
GP/primary care	600 (5.0%)	337 (6.0%)	0.0433
Specialist office	3,856 (32.4%)	1,341 (24.0%)	-0.1878

Community hospital	3,679 (31.0%)	1,731 (31.0%)	0.0013
University hospital	3,439 (28.9%)	1,910 (34.2%)	0.1139
Out-patient health care centre	184 (1.5%)	79 (1.4%)	-0.0110
Anticoagulation clinic	74 (0.6%)	28 (0.5%)	-0.0162
Physician specialty			
GP/PCP/Geriatrician	651 (5.5%)	148 (2.7%)	-0.1435
Cardiologist	9,702 (81.6%)	5,077 (91.0%)	0.2739
Internist	594 (5.0%)	144 (2.6%)	-0.1269
Neurologist	320 (2.7%)	133 (2.4%)	-0.0197
CHADS ₂ score, mean±SD	1.9±1.2	1.9±1.1	0.0222
CHADS ₂ score = 0	964 (8.1%)	394 (7.1%)	-0.0397
CHADS ₂ score = 1	4,051 (34.1%)	1,809 (32.4%)	-0.0355
CHADS ₂ score ≥ 2	6,868 (57.8%)	3,378 (60.5%)	0.0557
CHA ₂ DS ₂ -VASc score, mean±SD	3.2±1.5	3.2±1.5	-0.0364
CHA ₂ DS ₂ -VASc score = 1	1,408 (11.8%)	718 (12.9%)	0.0309
CHA ₂ DS ₂ -VASc score ≥ 2	10,476 (88.2%)	4,863 (87.1%)	-0.0309
HAS-BLED, mean±SD	1.3±0.8	1.2±0.9	-0.1571
HAS-BLED <3	9,846 (82.9%)	4,616 (82.7%)	-0.0038
HAS-BLED ≥3	898 (7.6%)	381 (6.8%)	-0.0282
Treatment with amiodarone	825 (6.9%)	1640 (29.4%)	0.6085
Antithrombotic prescription			
VKA alone	2,795 (23.5%)	1,291 (23.1%)	-0.0092
VKA + antiplatelets	470 (4.0%)	272 (4.9%)	0.0447
NOAC alone	7,434 (62.6%)	3,486 (62.5%)	-0.0019
NOAC + antiplatelets	1,185 (10.0%)	532 (9.5%)	-0.0148

Table 2: Log-Binomial regression analysis for the prediction of VKA prescription. Only patients who were anticoagulated, were included in the analysis.

	Patients N	VKA use N(%)	NOAC use N(%)	Univariate analysis	Multivariate analysis
				Relative risk (95% CI) for prescription of VKA use	Relative risk (95% CI) for prescription of VKA use
Baseline SAME-TT₂R₂					
Score >2	5581	1563 (28.0)	4018 (72.0)	1.019 (0.968, 1.073)	0.907 (0.856, 0.961)
Score ≤2	11884	3265 (27.5)	8619 (72.5)	1.0 (ref)	1.0 (ref)
Region					
Asia	2609	798 (30.6)	1811 (69.4)	1.022 (0.957, 1.091)	1.138 (1.054, 1.226)
Europe	9182	2747 (29.9)	6435 (70.1)	1.0 (ref)	1.0 (ref)
North America	4261	734 (17.2)	3527 (82.8)	0.576 (0.535, 0.619)	0.604 (0.560, 0.650)
Latin America	1413	549 (38.9)	864 (61.1)	1.299 (1.206, 1.395)	1.355 (1.254, 1.461)
Type of AF					
Paroxysmal	9319	2179 (23.4)	7140 (76.6)	1.0 (ref)	1.0 (ref)
Persistent	6301	1968 (31.2)	4333 (68.8)	1.336 (1.268, 1.407)	1.271 (1.207, 1.339)
Permanent	1845	681 (36.9)	1164 (63.1)	1.579 (1.470, 1.692)	1.372 (1.276, 1.472)
BMI class					
<18.5	199	58 (29.1)	141 (70.9)	1.015 (0.802, 1.250)	1.035 (0.820, 1.269)
18.5–<25	4484	1288 (28.7)	3196 (71.3)	1.0 (ref)	1.0 (ref)
25–<30/Missing	6807	1907 (28.0)	4900 (72.0)	0.975 (0.919, 1.036)	0.992 (0.934, 1.053)
30–<35	3559	954 (26.8)	2605 (73.2)	0.933 (0.869, 1.002)	0.982 (0.914, 1.055)
≥35	2416	621 (25.7)	1795 (74.3)	0.895 (0.824, 0.971)	1.031 (0.948, 1.119)
Prior bleeding					
Yes	862	248 (28.8)	614 (71.2)	1.043 (0.933, 1.158)	1.044 (0.936, 1.156)
No/Unknown	16603	4580 (27.6)	12023 (72.4)	1.0 (ref)	1.0 (ref)
Alcohol abuse					
Yes(≥8U/week)	1240	300 (24.2)	940 (75.8)	0.867 (0.781, 0.957)	0.881 (0.795, 0.972)
No(<8U/week/Unknown)	16225	4528 (27.9)	11697 (72.1)	1.0 (ref)	1.0 (ref)
Cancer					
Yes	1796	478 (26.6)	1318 (73.4)	0.959 (0.883, 1.038)	1.050 (0.968, 1.135)
No/Unknown	15669	4350 (27.8)	11319 (72.2)	1.0 (ref)	1.0 (ref)
Medical treatment reimbursed by					
Self-pay/No coverage	845	221 (26.2)	624 (73.8)	0.944 (0.837, 1.056)	0.785 (0.696, 0.880)
Not self-pay/Unknown	16620	4607 (27.7)	12013 (72.3)	1.0 (ref)	1.0 (ref)




Figure 1: Proportion of patients treated with VKA and NOAC by baseline SAME-TT₂R₂ score and region.




Figure 2: Proportion of patients treated with VKA and NOAC by baseline SAME-TT2R2 score and enrollment year.